ERIN Webinar on Bleeding Disorder of Unknown Cause (BDUC)
2025-11-18 18:00 - 19:00 (Europe/Brussels)
Following our successful 2025 webinars, we invite the bleeding disorders community to join us for the third and final session of the year, dedicated to the important topic of Bleeding Disorder of Unknown Cause (BDUC).
People living with BDUC experience symptoms similar to other inherited bleeding disorders, such as excessive bruising, heavy menstrual bleeding, or prolonged bleeding after surgery, yet the specific cause remains unidentified through current testing.
Organised in collaboration between European Haemophilia Consortium (EHC) and EAHAD, a European multi-disciplinary association of healthcare professionals (HCPs) who provide care for individuals with haemophilia and other bleeding disorders, this session aims to open a conversation on this under-recognised condition and begin lifting the veil of “unknown” that surrounds it.
The online event will take place on Tuesday, 18 November 2025, at 18:00 CET (dial-in details will be sent to registered participants one day in advance).
Featured Speakers:
Dr Saskia Schols – Internist-Haematologist, Medical Specialist, Radboudumc, The Netherlands
Dr Alison Dugall – head of the Department of Child and Dental Public Health at TRINITY College Dublin and a Consultant/Professor in Special Care Dentistry at Dublin Dental University Dental Hospital, Ireland
Mary Flanagan – Patient Representative
Jennifer Curley – Patient Representative
The webinar will feature clinical insights, available data, patient experiences, and an open discussion to promote understanding and collaboration within the bleeding disorders community.
The session will be held in English, with Russian interpretation available.
Whether you are a clinician, patient, caregiver, or advocate, your participation will help shed light on this complex and often overlooked condition.

IHS Clinical Webinar Series 2025: Rebalancing Agents in Haemophilia and Other Bleeding Disorders
2025-11-18 20:00 - 21:00 | Online
Featuring Dr. Johnny Mahlangu, Head of the Haematology Diagnostic Section in the Department of Molecular Medicine and Haematology at the University of the Witwatersrand, Johannesburg

IHS Clinical Webinar Series 2025: Update on Gene Therapy and Gene Editing in Haemophilia
2025-11-26 20:00 - 21:00 | Online
Featuring Professor David Lillicrap, Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario.

IHS Clinical Webinar Series 2025: Update on Mimetics
2025-12-02 20:00 - 21:00 | Online
Featuring Dr. Peter Lenting, National Institute for Health and Medical Research, Paris.

ASH Annual Meeting
2025-12-06 - 2025-12-09 | Orlando, Florida, United States
The American Society of Hematology (ASH) Annual Meeting is the world’s largest and most comprehensive haematology event of the year. With hundreds of sessions showcasing the latest research and practice trends in haematology, ASH offers multiple ways for attendees to find exactly what they are looking for.

IHS Clinical Webinar Series 2025: Access to Treatment – What Has Been Achieved Globally and What is Needed
2025-12-11 20:00 - 21:00 | Online
Featuring Dr. Glenn Pierce, Vice President Medical of the World Federation of Hemophilia (WFH), USA

EAHAD 2026 Congress
2026-02-03 - 2026-02-06 | The Convention Centre Dublin, Spencer Dock, N Wall Quay, North Wall, Dublin 1, D01 T1W6, Ireland, Dublin, Ireland

Clinical Implications of Roctavian’s Market Withdrawal
2026-04-07 17:30 - 18:30 | Online
The recent withdrawal of Roctavian from the market has raised important questions for clinicians, patients, and healthcare systems involved in the management of haemophilia A gene therapy. As the first approved GT medicine for adults with severe haemophilia A, Roctavian represented a significant milestone in the evolution of treatment options, and the effects of its withdrawal remain to be seen. This online session explores the clinical implications of its withdrawal, including considerations for patient management, ongoing monitoring of treated individuals, and the broader impact on the future of gene therapy in haemophilia.

Watch this insightful discussion on what this development means for clinical practice and the haemophilia community.

WFH Congress
2026-04-10 - 2026-04-16 | Kuala Lumpur, Malaysia, Malaysia
The WFH 2026 World Congress will include over 80 hours of continuing educational sessions across the Medical and People with Bleeding Disorders (PWBD) tracks, as well as six professional development tracks: Nursing, Dental, Laboratory Sciences, Psychosocial, Musculoskeletal (MSK) and Women and Girls with Bleeding Disorders (WGBD).

EHA2026 Congress
2026-06-11 - 2026-06-14 | Stockholm, Sweden, Sweden
The European Hematology Association (EHA) community consists of doctors (haematologists), researchers (PhD or otherwise), patients (and advocacy groups), geneticists, nurses, and more mainly across Europe, including non-EU member states.

Inhibitor Development in Gene Therapy for Haemophilia
2026-06-15 17:00 - 18:00 | Online
Gene therapy is transforming the treatment landscape of hemophilia, but major questions remain regarding its use in patients with current or past inhibitors. In this webinar, leading experts will discuss the most challenging clinical and immunological questions, from mechanisms of liver-induced tolerance to the management of inhibitors developing after gene transfer, and will debate whether eligibility criteria should evolve in light of emerging data.

ERIN Webinar: Understanding Haemophilia B With Inhibitors - From Daily Challenges to Clinical Management
2026-07-03 18:00 - 19:00 | Online

ISTH 2026
2026-07-11 - 2026-07-15 | Paris, France, France
ISTH is a worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and haemostasis.

EHC Conference 2026
2026-10-02 - 2026-10-04 | Istambul
